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Abstract 
Objective To investigate the profile, effects and toxicity of novel psychoactive substances 
(NPS). 
Methods A systematic literature review was conducted between May 2015 and February 2016 
and included 19 databases.  Search terms included: ‘novel psychoactive substance(s)’, 
‘effect(s)’ and ‘toxicity’ and their synonyms. Studies included were those from any country, in 
any language and between January 2007 and April 2015. Studies published before 2007 and 
those regarding the synthesis of NPS were excluded. Data was extracted by evaluating the 
titles, abstract and full text respectively. Consequently, the extraction yielded 20 studies. 
Results A total of 43 NPS derivatives of eight main pharmacological classes were identified. 
NPS were mostly used among young adults and adults within the age range of 16-64 years old. 
Cathinones and synthetic cannabinoids were the most prevalent amongst the aforementioned 
classes. The main desired effects of NPS use were empathy and increased ability to socialise. 
Reported toxicity associated with the use of NPS included cardiovascular, neurological and 
psychoactive adverse reactions.  
Conclusions Despite the unique subjective effects associated with the use of NPS, harmful 
effects could be severe and/or lethal. Therefore, there is a need to develop research in the area 
of NPS and promote awareness among healthcare professionals.   
 
Keywords Novel psychoactive substances, legal highs, cathinones, profile, effects, toxicity 
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Introduction 
Novel psychoactive substances (NPS) have emerged over the last decade as alternatives to 
classical drugs of abuse in order to surpass the regulations surrounding them (EMCDDA, 
2016a). These drugs have been continuously emerging at a rate of approximately twice a week 
(EMCDDA, 2016b). The European Monitoring Centre for Drugs and Drug Addiction 
EMCDDA reported more than 500 NPS derivatives available on the market in 2015 
(EMCDDA, 2016b).  
 
The increased number and diversity of NPS products imposed a burden on regulatory 
authorities and policy makers. With limited evidence on NPS health risks, it was difficult to 
introduce controls and new laws. Yet, once a law regarding an NPS derivative was introduced, 
another derivative was ready on the market. Hence, the UK introduced the New Psychoactive 
Substances Act (2016) which did not require the name of the NPS derivative in order to control 
it. 
 
NPS represent a major challenge in relation to their chemistry, pharmacology and toxicity. 
Though the general pharmacological classes of NPS were known; information regarding 
specific associated effects and toxicity is still limited (Patterson, Young & Vaccarino, 2017). 
This is mainly associated with the fact that most NPS were modifications of famous drugs that 
were not subject to clinical trials and/or drugs which failed clinical trials and withdrawn from 
the market. Other types of NPS included were medicines licenced in few countries only. For 
instance, phenazepam is licenced in Russia but not in the UK where it is sold (Corkery et al., 
2012). 
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The general effects reported from the use of NPS were stimulant (euphoria), hallucinogen 
(dissociative or psychedelics) and depressant effects (CNS inhibition) (Tracey, Wood & 
Baumeister, 2017). Yet, many specific effects were still underreported and this is partly due to 
the diversity of NPS users. NPS use is not limited to party scenes but could be encountered in 
users’ homes, individuals in custody and among psychonauts.  
 
Likewise, toxic effects associated with the use of NPS are underrepresented with only 
symptoms reported relating to agitation, aggression, cardiovascular toxicity, hyperthermia, 
palpitations, paranoia, psychotic symptoms and seizures (Tracey, Wood & Baumeister, 2017). 
Some specific symptoms are underreported. For instance, bladder toxicity associated with the 
use of methoxetamine (an NPS hallucinogen) was only identified in 2012 from users’ reports 
(Corazza et al. 2013). There is a growing concern over the harm associated with the use of NPS 
with increased emergency department admissions and demands for drug treatment (EMCDDA, 
2016b).  
 
Subsequently, we have conducted a comprehensive systematic review of the profile, effects 
and toxicity of NPS from the literature. We have provided analysis of studies which met the 
inclusion criteria. We then critically discussed our findings and summarised the evidence for 
the effects and toxicity of NPS. 
 
Methods 
Search strategy 
We searched the following 19 databases between May 2015 and February 2016: British 
Nursing Index, CINAHL, Cochrane Library, EBSCO, Embase, Global Health, Google, Google 
Scholar, International Pharmaceutical Abstracts, ISI Web of Science, JSTOR, Medline, 
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National Electronic Library for Medicine (NeLM), PsychExtra, PsychInfo, PubMed, 
ScienceDirect and Scopus. The search strategy evaluated articles retrieved predominantly 
through databases. We also retrieved bibliographic lists from published reviews where 
relevant. 
 
We used the following search terms: ‘novel psychoactive substances’, ‘effects’ and ‘toxicity’. 
The search strategy involved use of the three terms in each database as follows: ‘novel 
psychoactive substance(s)’ OR ‘legal high(s)’ OR ‘designer drug(s)’ OR ‘bath salt(s)’ OR 
‘herbal high(s)’ OR ‘novel recreational drugs’ OR ‘party drugs’ AND ‘effect(s)’ OR 
‘effectiveness’ OR ‘efficacy’ AND ‘toxicity’ OR ‘harm’ OR ‘side effect(s)’ OR ‘adverse 
effect(s)’ OR ‘adverse reaction(s)’ OR ‘overdose’ OR ‘drug interaction(s)’. 
 
Inclusion criteria 
Studies were included in the systematic review if they investigated the effects and toxicity 
associated with NPS, published from 2007 onwards and had explicit data on young adult- 
and/or adult-population (above 15 years). 
 
Exclusion criteria  
Three types of studies were excluded from the review. The first type were studies that 
encompassed information regarding the synthesis and analytical characterisation of NPS. The 
second type were studies that investigated NPS among children < 15 years old. The third type 
were studies that investigated receptor pharmacology through animal models.  
 
List of definitions 
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An adverse drug reaction (ADR) is defined as “ any noxious, undesired and unintended drug 
effect that occurs at doses used in human for therapy, diagnosis or prophylaxis” (WHO, 1972). 
Oral intake of a drug involves direct swallowing of the formulation as a tablet, powder 
dissolved in a liquid, or powder wrapped in a cigarette paper (bombing). Intravenous (IV) and 
intramuscular (IM) intake of a drug comprises the injection of the drug solution into a vein or 
muscle respectively. Nasal insufflation involves the snorting of the NPS powder. 
 
Data extraction 
Data extraction was conducted by the authors and included the following information: study 
type (case report, user report, interview, survey), country, study settings, population age, study 
aim, duration and sample size. Articles were scanned independently and systematically by two 
reviewers (SA and NG), and the screening process included titles, abstracts and full articles. 
Disagreement among reviewers was resolved by discussion. When the inclusion and exclusion 
criteria were applied, a third reviewer (DO) verified the data. 
 
Results 
In total, 11,550 studies were retrieved (Figure 1) before applying the limitation of time (beyond 
2007) and age (≥ 15 years old) limits. When applying inclusion/exclusion criteria and removing 
duplicates, 648 studies were obtained. Upon inspection of titles 386 studies remained. Out of 
the 386, 333 were excluded because they did not consider NPS. The abstracts of the remaining 
53 studies were evaluated and 33 were found not relevant. The search resulted in 20 studies 
which investigated effects and toxicities associated with NPS. 
 
Study characteristics 
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Studies extracted in this review were from 10 countries (Table 1) including Australia (Goggin, 
Gately & Bridle, 2015), France (Eiden et al., 2013), Italy (Gerace et al., 2014), Netherland 
(Hondebrink et al.,2015), Norway (Karinen et al., 2014), Poland (Kulhawik & Waleski, 2015; 
Rojek et al., 2012), Singapore (Winslow & Mahedran, 2014), Spain (Gonzalez et al., 2013; 
Papaseit et al., 2013), the UK (Arora, Kumar & Raza, 2013; Dargan & Wood, 2012; Winstock 
et al., 2011) and the USA (Antonowicz et al., 2011; Belton et al. 2012; Borek, Christopher & 
Holstege, 2012; Kelly, 2011; Spiller et al., 2011; Stogner & Miller, 2013; Lajoie & Rich, 2012). 
The majority of the studies were retrospective and fewer were prospective. Retrospective 
studies included audit (n = 2) (Hondebrink et al., 2015; Spiller et al., 2011) and case report (n 
= 11) (Antonowicz et al., 2011; Arora, Kumar & Raza, 2013; Belton et al. 2012; Borek, 
Christopher & Holstege, 2012; Eiden et al., 2013; Gerace et al., 2014; Karinen et al., 2014; 
Kulhawik and Walecki, 2015; Rojek et al., 2012; Lajoie & Rich, 2012; Winslow & Mahedran, 
2014). Prospective studies included interview/telephone interview (n = 2) (Kelly, 2011; 
Winstock et al., 2011), observational (n = 1) (Papaseit et al., 2013) and survey (n = 4) (Goggin, 
Gately & Bridle, 2015; Gonzalez et al., 2013; Kelly et al., 2013; Stogner & Miller, 2013). The 
age groups reported in the 24 studies included mainly young adults and adults (range 15-64 
years old). The sample size investigated had a minimum of 1-2 (for case reports) and a 
maximum of 42,243 (for retrospective audit). The duration of the studies ranged between few 
hours to few years. 
 
NPS class, formulation and modality of intake 
A total of 43 NPS derivatives were reported in the studies and were used as cognitive 
enhancers, empactogenic or euphoric agents, hallucinogens and/or stimulants (Table 2).  The 
NPS derivatives were of the following pharmacological classes: cathinones (n=18) 
(Antonowicz et al., 2011; Belton et al., 2013; Eiden et al., 2013; Gerace et al., 2014; Gonzales 
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et al., 2013; Hondebrink et al, 2015; Kelly et al., 2013; Papaseit et al., 2013; Stogner & Miller, 
2013; Winslow & Mahedran, 2014), kratom (n = 1) (Karinen et al., 2014); opioids (n = 1) 
(Karinen et al., 2014), ketamines/phenethylamines/piperidine (n = 9) (Gonzales et al., 2013; 
Hondebrink et al., 2015), Salvia (n = 2) (Kelly, 2011; Winslow & Mahedran, 2014), synthetic 
cannabinoids (n = 6) (Antonowicz et al., 2011; Arora, Kumar & Raza, 2013; Goggin, Gately 
& Bridle, 2015; Hondenbrink et al., 2015; Kelly et al., 2013) and tryptamines (n = 2) 
(Hondebrink et al., 2015).  
 
For the formulation of NPS used, 15 (62.5%) studies described the use of powder NPS 
products, six (25%) reported tablets, four (16.7%) reported herbal material and one (4.16%) 
reported liquids. Regarding the modality of intake of NPS, oral route was reported by 12 (50%) 
of studies and comprised both direct swallowing or bombing of the substance. Other routes 
used for intake of NPS were smoking, nasal insufflation, IV, IM and rectal and were reported 
by 10 (41.6%), eight (3.33%), seven (2.92%), two (8.33%) and one (4.16%) study respectively. 
The frequency of intake was mainly acute (among 14 studies) and only six studies reported 
chronic use.  
 
Most of the NPS products were used in conjunction with alcohol (n = 10), energy 
drinks/caffeine (n = 2), tobacco (n = 1) and or classical drugs (n = 11). The aforementioned 
classical drugs were: amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, ecstasy, 
lysergic acid diethylamide (LSD), marijuana, methylenedioxymethamphetamine (MDMA), 
magic mushrooms, methadone, oxazepam, opiates, oxycodone and oxymorphone. 
 
NPS effects 
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Users from seven (29.1%) studies reported achieving the desired effects as a result of the 
recreational use of NPS.  The aforementioned desired effects encompassed four categories: 
empathogenic, hallucinogen or stimulant effects. Empathogenic effects included “being 
compassionate” and “feeling of social intimacy”. Hallucinogen effects were extracampine 
hallucinations, vivid auditory and visual hallucinations, and a change of time perception. 
Stimulant effects included euphoria, increased alertness, increased sexual desire, enhanced 
cognitive skills and prosocial effects. 
 
NPS toxicity 
Toxicity of NPS derivatives included two main categories: ADR and drug overdose. ADRs 
were reported in 14 studies and were associated with newer amfetamine analogues, cathinones, 
ketamine derivatives and herbal highs. Newer amfetamine analogues and cathinones were 
associated with cardiovascular, neurological, psychotic, renal and respiratory effects 
(Antonowicz et al., 2011; Borek, Christopher & Holstege, 2012; Eiden et al. 2013; Gonzalez 
et al. 2013; Hondebrink et al., 2015; Lajoie & Rich, 2012; Papaseit et al. 2013; Spiller, 2011; 
Winstock et al., 2011). Reported cardiovascular ADRs associated with cathinones included 
cardiac arrest, chest pain, hypertension, palpitations, tachycardia and vasoconstriction.  
Nervous system ADRs included coma, confusion, drowsiness, fatigue, headache, 
hyperthermia, hypothermia, increased muscle tone, insomnia, loss of appetite, loss of 
concentration, mydriasis, nausea, numbness, seizures, tremors, vertigo, vomiting and 
weakness. Psychotic ADRs included agitation, anxiety, confusion, depression, irritability, 
paranoia, psychosis, psychotic breakdown, self-harming and suicidal thoughts. Only two 
ADRs were reported for each of the renal and respiratory systems and were urinary tract 
infection and pulmonary edema respectively. Novel ketamine analogues (methoxetamine) and 
herbal highs (artificial hashish, Kratom, Salvia) were associated mainly with psychotic ADRs 
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such as vivid, visual and auditory hallucinations (Hondebrink et al. 2015; Kelly, 2011; 
Winslow & Mahedran, 2014). Additionally, a case of hypoxemic respiratory insufficiency due 
to artificial hashish was reported (Kulhawik & Waleski, 2015). 
 
Only three studies reported lethal overdose associated with the use of NPS, and included both 
accidental (Gerace et al., 2014; Karinen et al., 2014) and deliberate overdose (Rojek et al., 
2012). The above mentioned three cases involved the use of kratom, butylone and mephedrone 
respectively. 
 
 
Discussion 
To our knowledge, this is the first systematic review to investigate the profile, effects and 
toxicity involving NPS within an adult population. Three other reviews were reported in the 
literature in relation to NPS. A recent systematic review investigated the prevalence of NPS 
in non-clinical population (Khaled et al. 2016). Yet, it did not examine in depth the toxicities 
associated with NPS. A second review investigated the effects of NPS but was limited to 
population with severe mental illness (Gray et al. 2016). Another systematic review has been 
published regarding the effects and risks associated with NPS (Hohmann, Mikus & Czock, 
2014). However, the scope of the latter review was limited to publications between 2010 and 
2012 years. Our review considered all studies since 2007 (marked as the year of emergence of 
NPS) up to 2015.  
 
Our findings suggested that NPS were highly prevalent among young adults and adult 
populations. Cathinones were the most prevalent NPS derivatives followed by synthetic 
cannabinoids. This result confirmed the outcomes of other studies which showed that 
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cathinones and synthetic cannabinoids were the most reported substances to the EMCDDA 
(Hohmann, Mikus & Czock, 2014; Martinotti et al. 2015; Stephenson and Richardson 2014).  
 
Powdered NPS-formulations were preferred over tablet/capsules. This could be attributed to 
the increased availability of powder formulations, ease of use and ability to be used in multiple 
routes (either directly or via mixing with a liquid). The main routes for NPS intake were oral 
(by swallowing) and IV (by injecting) routes. This finding was supported by Schmidt et al. 
(2011) who identified that around 60% of NPS derivatives were designed to be swallowed. 
NPS were often mixed with alcohol and classical drugs of abuse (such as cocaine). This finding 
confirmed previous studies where poly drug use was witnessed among NPS and other 
psychoactive substances/alcohol (Davey et al., 2012; Corbo et al. 2015). Poly drug use could 
attribute to unpredictable drug interactions that depend to a degree on the purity of the NPS 
present.  
 
Little information regarding the effects of NPS was extracted in this review. This could be 
attributed to the fact that the majority of the included studies were case reports of toxicity. 
Where reported, users were interested in the unique subjective experience achieved upon intake 
of NPS. Among other effects, users experienced empathy and increased socialising ability 
when taking stimulants (Newcombe, 2009). Likewise, users taking phencyclidine derivatives 
had vivid/auditory hallucinations and near-death experience (Corazza et al., 2012; Corazza, 
Assi & Schifano, 2013). 
 
Despite achieving the desired effects, numerous ADRs were associated with the use of NPS 
and included both physical and neuropsychiatric symptoms. Common cases involved psychotic 
breakdown.  In severe cases, ADRs led to respiratory depression, cardiac arrest or multiple 
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organ failure. Lethal effects were also seen with both accidental and deliberate overdose of 
NPS. This could be critical in the current changing scenario of drug abuse where multiple 
factors play a role in the efficacy/safety of drugs. These factors include polydrug use, different 
routes of intake and different dosing intervals of drugs (Corazza et al., 2013). Henceforth, 
further research and healthcare education is needed in order to tackle issues associated with 
NPS. 
 
Strength and limitations  
This systematic review involved investigating data from previous studies by two independent 
reviewers. The studies included in the review were further verified by a third independent 
reviewer in order to avoid bias. For each study, the inclusion/exclusion criteria were applied to 
achieve the research objectives, to identify the profile, effects and toxicity associated with the 
use of NPS. Nonetheless, the systematic review had some limitations. Due to the limited 
number of studies available, it was not possible to get the profile of NPS per country. Moreover, 
information extracted from this review was restricted mainly to case reports/emergency 
department admissions. Major information was missing regarding demography of participants, 
first time exposure to drug, time of intake of drugs and scene where the drug was taken. This 
influenced the understanding of the effects and toxicity associated with drugs. It was not 
possible to identify drug interactions associated with polydrug use. Furthermore, it was not 
possible to correlate the exact effects associated per specific NPS derivative. This was because 
when subjects were reported to the emergency department no confirmatory testing was 
undertaken on blood or urine to correlate the signs and symptoms with what was actually 
consumed. Instead, physicians treat the symptoms and then discharge patients when the 
symptoms have worn off. Moreover, it was not possible to obtain conclusive data regarding 
severity and preventability, which were not reported in any of the studies. The heterogeneity 
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of the data in this review was mainly attributed to differences between countries, study settings, 
sample size and duration. Hence, it was not possible to make a conclusive judgement for all 
countries. 
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Figure legend 
Figure 1. Data extraction and the study selection process 
List of tables 
 
Table 1. Characteristics of the studies that investigated novel psychoactive substances 
Study Year Country Study type Study settings Age Aim Duration Sample 
size 
Prospective studies 
Goggin et al 2015 2013 Australia Questionnaire 
survey 
Young Adults participated in the 
survey 
18-35 years 
old 
To obtain data on prevalence 
of NPS and other drug use by 
young Western Australians. 
6 months 682 
Gonzalez et al 
2013 
2010-
2011 
Spain Questionnaire 
survey 
Music festivals and online drug 
forums 
adults 
average age 
27 years old 
To know the pattern of use of 
NPS in a Spanish sample of RC 
users and to deepen the RC user 
profile and risk reduction 
strategies 
10 months 230 
Kelly, 2011 2008-
2009 
USA Interview Users' homes, parks, 
bars and parties. 
19-29 years  
old 
To present data from 
an ethnographic project 
to provide a qualitative  
profile of Salvia use among  
young adults. 
1 year 25 
Kelly et al 2013 2012 USA Questionnaire 
survey 
Nightclub venues in 
New York City  
18-40 years  
old 
To gain an indication of the 
prevalence and understanding of 
demographic factors associated 
with mephedrone and synthetic 
cannabinoid use 
6 months 1740 
Papaseit et al 
2013 
2013 Spain Observational outpatient clinic NR To obtain preliminary  
data regarding mephedrone 
effects 
3 days 9 
Stogner et al 
2013 
2012 USA Questionnaire 
survey 
Southeastern US university adults of mean  
age 20.06 
years old 
Gain understanding about the 
prevalence of synthetic 
cathinones 
3 months 2349 
Winstock et al 
2011 
2009 UK Telephone  
interview 
Telephone questionnaires 20-25 
minutes each 
adults of mean 
age of 25.1 for 
males 
and 23 for 
females 
To describe initiation to 
mephedrone and patterns of use, 
assess acute and withdrawal 
effects, and assess the 
prevalence of dependence 
symptoms 
3 months 100 
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Retrospective studies 
Antonowicz  
et al 2011 
2011 USA Case report General hospital 27 years old 
and 32 years 
old 
To investigate two cases  
of a paranoid psychosis 
in individuals consuming 
MDPV 
4 days 2 
Arora et al 2013 2013 UK Case report A 56-year-old male attending 
A&E after inhaling unknown 
quantity of synthetic 
cannabinoid called 'herbal haze' 
few hours before. 
56 years  
old male 
To present the first described 
case of a ‘legal high’ intake linked 
to a posterior circulation stroke. 
4 days 1 
Belton et al 2013 2012 USA Case report Hospital 34 , 39 and 38 
years old 
To report three different  
cases regarding MRSA 
secondary to intravenous 
bath salts use. 
55, 42 and 14 days 3 
Borek & Holstege  
2012 
2011 USA Case report Hospital emergency department 25 years old Toxicity resulting from injecting 
bath salts. 
1 month 1 
Eiden et al 2013 2012 France Case report Hospital 32 and 21 
years old 
To investigate death associated 
with 2-PVP 
30 minutes and 1 
day 
2 
Gerace et al 2014 2014 Italy Case report Apartment 25 years old To investigate the cause  
of death 
2 days 1 
Hondebrink  
et al 2015 
2007-
2013 
Nertherlands Audit DIMS drug testing facilities 15-41  
years old 
To obtain data regarding 
NPS-related intoxications from 
drug users in Netherlands 
6 years 42,243 
Karinen et al 
2014 
2013 Norway Case report Home Middle aged To investigate the cause  
of death 
3 days 1 
Kulhawik &  
Waleski 2015 
2014 Poland Case report Hospital lung disease 
department 
20 years old To investigate the lung injury 
associated with the use of artificial 
hashish 
5 weeks 1 
Lajoie & Rich  
2012 
2011 USA Case report Hospital 50 years old To investigate MDPV intoxication 15 days 1 
Rojek et al 2012 2012 Poland Case report Hospital 21 years old to investigate methylone 
deliberate overdose 
4 hours 1 
Spiller et al 2011 2010-
2011  
USA Audit Two poison centres 16-64 years  
old 
To report the experience 
of synthetic cathinones in two 
regional poison centers 
13 months 236 
Winslow & 
Mahedran 2014 
2014 Singapore Case report Home 30 years old To investigate acute 
Salvia intoxication 
45 minutes 1 
2-PVP: 2-pyrrolidinovalerophenone, A&E: accident and emergency, DIMS: Drug Information and Monitoring System, MDPV: methylenedioxypyrovalerone, MRSA: methicillin resistance staphylococcus aureus, 
NPS: novel psychoactive substances, NR: not reported, RC: research chemical 
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Table 2. Modalities of intake of novel psychoactive substances 
Study NPS(s) used Formulation Modality of intake Combination of drugs 
Antonowicz et al 2011 MDPV, herbal incense solution, powder oral and insufflation energy drink; case and Suboxone 
Arora et al 2013 synthetic cannabinoids plant smoking tobacco, alcohol and cannabis 
Belton et al 2013 mephedrone and methylone liquid IV none 
Borek & 
Holstege 2012 
MDPV liquid IV none 
Eiden et al 2013 2-PVP powder insufflation  cannabis and alcohol 
Gerace et al 2014 mephedrone powder oral ingestion alcohol and cocaine 
Goggin et al 2015 synthetic cannabinoids plant smoking alcohol, energy drinks and tobacco 
Gonzalez et al 2013 mephedrone, methylone and PEA powder oral and insufflation cannabis, alcohol and MDMA 
Hendebrink et al 2015 2C-B, 4-FA, 6-APB, mephedrone and 
MXE 
powder 
and tablet 
insufflation, IV, oral and 
smoking  
MDMA, amphetamine,  
alcohol and cocaine 
Karinen et al 2014 kratom powder oral none 
Kelly et al 2013 mephedrone and synthetic  
cannabinoids 
powder and 
plant 
smoking and insufflation alcohol and other drugs 
Kelly, C.B., 2011 Salvia divinorum plant smoking LSD, psilocybin 
Kulhawik & Waleski 2015 artificial hashish plant smoking marijuana, alcohol and tobacco 
Papseit et al 2013 mephedrone powder oral MDMA 
Rojek et al 2012  methylone tablet oral none 
Spiller et al 2011 cathinones and MDPV powder insufflation, IV and oral  amphetamines, barbiturates, benzodiazepines, 
caffeine, cannabinoids, cocaine, MDMA, 
methadone, opiates, oxycodone and 
oxymorphone 
Stogner et al 2013 cathinones and MDPV powder oral and insufflation alcohol 
Lajoie a& Rich 2012 MDPV powder IV none 
Winslow & 
Mahedran 2014 
Salvia plant smoking none 
Winstock et al. 2011 mephedrone powder oral and insufflation alcohol, cannabis, cocaine and ecstasy 
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2-CB: 2,5-dimethoxy-4-bromophenethylamine, 2-PVP: 2-pyrrolidinovalerophenone, 4-FA: 4-fluoroamphetamine, 6-APB: 6-2aminopropylbenzofuran, IV: intravenous injection, LSD: lysergic acid diethylamide, 
MDMA: methylenedioxymethamphetamine, MDPV: methylenedioxypyrovalerone, MXE: methoxetamine, PEA: phenethylamine.  
